Merus (MRUS) Competitors $64.15 +0.89 (+1.41%) Closing price 04:00 PM EasternExtended Trading$62.55 -1.60 (-2.50%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MRUS vs. ITCI, GMAB, MRNA, RDY, VTRS, QGEN, ASND, BBIO, VRNA, and BPMCShould you be buying Merus stock or one of its competitors? The main competitors of Merus include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Merus vs. Its Competitors Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Merus (NASDAQ:MRUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Does the media refer more to ITCI or MRUS? In the previous week, Merus had 8 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 8 mentions for Merus and 0 mentions for Intra-Cellular Therapies. Merus' average media sentiment score of 0.38 beat Intra-Cellular Therapies' score of 0.29 indicating that Merus is being referred to more favorably in the news media. Company Overall Sentiment Intra-Cellular Therapies Neutral Merus Neutral Which has higher valuation and earnings, ITCI or MRUS? Intra-Cellular Therapies has higher revenue and earnings than Merus. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64Merus$36.13M122.88-$215.33M-$4.08-15.72 Do analysts rate ITCI or MRUS? Intra-Cellular Therapies currently has a consensus target price of $109.70, indicating a potential downside of 16.81%. Merus has a consensus target price of $84.64, indicating a potential upside of 31.94%. Given Merus' stronger consensus rating and higher probable upside, analysts clearly believe Merus is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14 Do institutionals and insiders believe in ITCI or MRUS? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 96.1% of Merus shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 4.6% of Merus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, ITCI or MRUS? Intra-Cellular Therapies has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Merus has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Is ITCI or MRUS more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Merus' net margin of -506.73%. Intra-Cellular Therapies' return on equity of -9.93% beat Merus' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Merus -506.73%-35.99%-29.83% SummaryMerus beats Intra-Cellular Therapies on 11 of the 17 factors compared between the two stocks. Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRUS vs. The Competition Export to ExcelMetricMerusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44B$3.04B$5.66B$9.45BDividend YieldN/A2.49%4.01%4.02%P/E Ratio-15.7221.3928.0720.12Price / Sales122.88275.08417.5199.64Price / CashN/A41.6635.9658.29Price / Book6.788.188.555.81Net Income-$215.33M-$55.10M$3.24B$258.18M7 Day Performance13.52%7.63%4.86%3.98%1 Month Performance21.63%21.73%13.00%14.81%1 Year Performance15.54%6.45%35.57%19.30% Merus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRUSMerus2.1041 of 5 stars$64.15+1.4%$84.64+31.9%+13.4%$4.44B$36.13M-15.7237Upcoming EarningsAnalyst DowngradeITCIIntra-Cellular Therapies0.9912 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0545 of 5 stars$21.46+0.3%$37.80+76.1%-21.6%$13.77B$3.12B12.192,682Analyst DowngradeGap UpMRNAModerna4.284 of 5 stars$32.87-2.3%$46.61+41.8%-73.3%$12.71B$3.24B-3.775,800Analyst ForecastGap UpRDYDr. Reddy's Laboratories2.9692 of 5 stars$14.58+0.4%$16.95+16.3%-9.9%$12.17B$325.54B22.0827,811News CoverageEarnings ReportUpcoming EarningsVTRSViatris2.4754 of 5 stars$9.14+0.2%$10.40+13.8%-20.8%$10.73B$14.74B-2.8832,000QGENQiagen3.7527 of 5 stars$48.25+0.3%$49.40+2.4%+20.5%$10.73B$1.98B120.985,765Positive NewsASNDAscendis Pharma A/S3.6262 of 5 stars$174.880.0%$223.07+27.6%+21.4%$10.69B$393.54M-27.851,017Positive NewsBBIOBridgeBio Pharma4.6138 of 5 stars$47.69+2.6%$61.20+28.3%+71.6%$9.06B$221.90M-13.51400Upcoming EarningsAnalyst ForecastVRNAVerona Pharma PLC American Depositary Share2.7224 of 5 stars$104.67-0.2%$109.00+4.1%+359.0%$8.91B$42.28M-52.3430High Trading VolumeBPMCBlueprint Medicines1.0077 of 5 stars$129.36+0.0%$128.25-0.9%N/A$8.35B$508.82M-52.37640Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRUS) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRUS Stock Alerts